Phase 3 Lung Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with a specific type of lung cancer (non-squamous non-small cell lung cancer) that has been confirmed by a tissue or cell sample, and whose cancer has a particular genetic change called a KRAS G12C mutation (found in a tumour sample or a blood test).
• People whose lung cancer has spread to nearby areas or to other parts of the body.
• People whose cancer has at least one measurable tumour, as seen on a CT or MRI scan.
• People who have not yet received any systemic (whole-body) anti-cancer treatment for their advanced or metastatic disease.
• People for whom curative treatments such as surgery or combined chemotherapy and radiation are not considered appropriate options by their treating doctor.
• People who have cancer that has spread to the brain may still be considered, including those whose brain tumours have not yet been treated, provided the brain tumours are causing no symptoms, do not need urgent treatment, and are no larger than 20mm in size.
• People whose tumours show any level of a protein called PD-L1 (from 0% to 100%), as measured by one of three specified approved laboratory tests.

Who may not be able to join:

• People who have an active autoimmune or inflammatory condition that has required systemic (whole-body) medical treatment at any point in the past two years.
• People who have had significant or uncontrolled heart or blood vessel problems within the past six months, or where there is an ongoing risk of those problems returning.
• People whose blood test results show that bone marrow or liver function is not at an adequate level, or whose heart rhythm test (ECG) shows certain abnormalities.
• People who are currently taking medications known to affect heart rhythm in a specific way (called QTc prolongation) and for whom switching to a different medication before joining the trial is not possible.
• People who have previously received any treatment that specifically targets the KRAS G12C mutation, such as sotorasib or adagrasib, in any context.
• People who have another serious ongoing medical, psychiatric, or laboratory condition that the trial team considers would increase the risks associated with taking part.
• Additional criteria defined in the full trial protocol also apply (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.